Blackhawk’s MindBio Therapeutics Ahead of Schedule to Complete Phase 1 Clinical Trial Microdosing of Psychedelic Medicines and Provides Updates on Spinout Process
Vancouver, British Columbia – TheNewswire – January 24, 2022 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its subsidiary MindBio Therapeutics Pty Ltd. (“MindBio”) has entered into the final stage of a Phase 1 clinical trial involving microdosing LSD and is on track for completion in March 2022, ahead of its original 12 month schedule.
At completion of the Phase 1 trial, MindBio will have important data and intellectual property on microdosing of medical psychedelics. Having successfully passed the Phase 1 clinical trial’s independent Data and Safety Monitoring Committee and with no adverse events, MindBio is confident it has sufficient data, protocols and strategy for its next phase of clinical trials.
MindBio has also started preparation work for a Phase 2 clinical trial which includes the design of its proprietary psychedelic microdosing formulations that can subsequently be manufactured under Good Manufacturing Practices (GMP) standards for subsequent use both commercially and in clinical trials.
MindBio is working towards creating a safe and effective microdosing regimen using psychedelics that can be prescribed by doctors to patients in the primary health care system. In larger doses, LSD is a hallucinogenic drug that substantially changes cognition, thinking, mood and perception, however in much smaller “microdoses”, the medicine is subperceptual, meaning that patients can take the drug without noticing its hallucinogenic effects, but still receive the medicinal benefit and get on with their normal day.
MindBio wants to be the first to market by commercializing a microdosing regimen with substantial potential global mental health care benefits that:
- have potentially lower side effect risk profile to existing pharmacological treatments such as anti-depressants and benzodiazapines for the treatment of a range of mental health conditions;
- offer less risk of harm than large, one-off doses of psychedelics;
- affect’s brain neuroplasticity after acute administration, in the same way that larger hallucinogenic doses affect the brain, yet the patient is still able to get on with their normal day after ingesting the microdose. This is not possible with a psychedelic macro-dosing treatment session which requires an in clinic therapeutic session guided by clinicians over many hours; and
- is a scalable solution to global mental health treatment.
The results of this important clinical trial will form the basis for advancing the commercialization of a psychedelic microdosing regimen for safe use in the community.
Update on Spinout Process
Blackhawk is also pleased to report that MindBio is well underway with its proposed spinout.
In December 2021, Blackhawk announced its intention to spinout MindBio as well as Digital Mind Technology, both wholly-owned subsidiaries of Blackhawk, into a newly formed subsidiary of spinco. It is aniticipated that the spinco will ultimately pursue a separate public listing.
The Company is pleased to report that since the announcement, the Company and its subsidiaries have appointed their legal teams and have progressed with preparation of materials to complete the spinout.
MindBio intends to create a focused multi-disciplinary platform for one of the most progressive psychedelics and mental health development companies in the world with four (4) clinical trials in development and underway this year. Using novel drug development, microdosing psychedelics, assisted therapies and technology, MindBio is working towards changing the way that mental health disorders are treated.
It is anticipated that the spin out and listing of MindBio will create significant shareholder value as each Blackhawk shareholder will receive one common share in the newly listed spinco for every share held in Blackhawk, on a pro rata basis, based on a record date that is expected to be set after shareholder and regulatory approvals are received. The Company is expecting to make further announcements on the timetable of the spinout as it becomes available.
“All of our portfolio companies are making significant progress these days”, said Frederick Pels, CEO of Blackhawk. “Our management teams at MindBio and Digital Mind Therapeutics are working hard to complete this Phase 1 clinical trial and move onto its Phase 2, which I am pleased to report is tracking ahead of schedule, bringing us another step closer to commercializing our unique microdosing protocol. In addition, there has been substantial progress on the necessary steps to facilitate our proposed spinout. I look forward to updating shareholders as we progress further.”
About Blackhawk Growth
Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes TERP Wholesale, Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics and Digital Mind Technology, as well as an equity position in Gaia Grow (CSE:GAIA).
The Company diligently posts updates through videos from the official company YouTube channel www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please visit us online at www.blackhawkgrowth.com.
For further information please contact:
Frederick Pels, Chief Executive Officer
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to of the intended spinout of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.